Sol-Gel Technologies (SLGL) Stock Forecast, Price & News

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sol-Gel Technologies in the last twelve months. There are currently 1 hold rating, 1 buy rating and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" SLGL shares.
View SLGL analyst ratings or view top-rated stocks.

3 Wall Street research analysts have issued 12 month price targets for Sol-Gel Technologies' shares. Their SLGL share price forecasts range from $5.50 to $19.00. On average, they expect the company's stock price to reach $11.50 in the next twelve months. This suggests a possible upside of 219.4% from the stock's current price.
View analysts price targets for SLGL or view top-rated stocks among Wall Street analysts.

Sol-Gel Technologies' stock was trading at $4.5599 at the start of the year. Since then, SLGL stock has decreased by 21.1% and is now trading at $3.60.
View the best growth stocks for 2023 here.

Sol-Gel Technologies saw a decrease in short interest in May. As of May 15th, there was short interest totaling 48,200 shares, a decrease of 24.5% from the April 30th total of 63,800 shares. Based on an average daily volume of 16,600 shares, the short-interest ratio is presently 2.9 days. Currently, 0.4% of the company's stock are short sold.
View Sol-Gel Technologies' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our SLGL earnings forecast.

Sol-Gel Technologies Ltd. (NASDAQ:SLGL) posted its quarterly earnings results on Friday, March, 10th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by $0.12. The business had revenue of $0.10 million for the quarter, compared to analyst estimates of $1.85 million. Sol-Gel Technologies had a negative trailing twelve-month return on equity of 42.56% and a negative net margin of 422.45%.

Invesco Raymond James SB-1 Equity ETF holds 9,374 shares of SLGL stock, representing 0.03% of its portfolio.

Based on aggregate information from My MarketBeat watchlists, some companies that other Sol-Gel Technologies investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Flexion Therapeutics (FLXN), Iovance Biotherapeutics (IOVA), Marker Therapeutics (MRKR), Teva Pharmaceutical Industries (TEVA), Viking Therapeutics (VKTX), Verona Pharma (VRNA) and Adaptimmune Therapeutics (ADAP).

(SLGL) raised $60 million in an IPO on Thursday, February 1st 2018. The company issued 5,000,000 shares at a price of $11.00-$13.00 per share. ​Jefferies and BMO Capital Markets​ acted as the underwriters for the IPO and JMP Securities and Raymond James​ were co-managers.

Sol-Gel Technologies trades on the NASDAQ under the ticker symbol "SLGL."

Sol-Gel Technologies' stock is owned by many different retail and institutional investors. Top institutional investors include Armistice Capital LLC (10.41%), Kingdon Capital Management L.L.C. (3.33%), Raymond James Financial Services Advisors Inc. (0.26%), Raymond James & Associates (0.16%) and Simplex Trading LLC (0.00%).

Shares of SLGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SLGL stock can currently be purchased for approximately $3.60.

Sol-Gel Technologies (NASDAQ:SLGL) has a market capitalization of $83.27 million and generates $3.88 million in revenue each year. The company earns $-14,920,000.00 in net income (profit) each year or ($0.82) on an earnings per share basis.

Sol-Gel Technologies' mailing address is 7 GOLDA MEIR ST. WEIZMANN SCIENCE PARK, NESS ZIONA L3, 7403648. The official website for the company is www.sol-gel.com. The company can be reached via phone at (728) 931-3433, via email at crusso@soleburytrout.com, or via fax at 972-153-523044444.